Literature DB >> 10188906

Prognostic significance of angiogenesis in human pancreatic cancer.

N Ikeda1, M Adachi, T Taki, C Huang, H Hashida, A Takabayashi, M Sho, Y Nakajima, H Kanehiro, M Hisanaga, H Nakano, M Miyake.   

Abstract

To evaluate whether angiogenic factors are of clinical relevance to actual human pancreatic cancers, we studied the intratumoral microvessel density (IMD), and PD-ECGF, VEGF protein expression in 40 pancreatic cancers using immunohistochemistry. We also investigated PD-ECGF and VEGF gene expression using reverse transcriptase-PCR (RT-PCR). Of the 40 pancreatic cancers studied, 30 carcinomas (75.0%) were evaluated to be PD-ECGF-positive and 10 carcinomas (25.0%) were determined to be PD-ECGF-negative. In contrast, 27 carcinomas (67.5%) were evaluated to be VEGF-positive, whereas 13 carcinomas (32.5%) were VEGF-negative. VEGF gene expression was moderately associated with an increase in the IMD (r2 = 0.181, P = 0.006), but no significant relationship was found between PD-ECGF gene expression and the IMD (r2 = 0.093, P = 0.059). However, tumours with positive expression for both PD-ECGF and VEGF had a higher IMD (P = 0.027). The results of the immunohistochemistry agreed well with the results of the quantitative RT-PCR. The median survival time of the hypervascular group was significantly shorter than that of the hypovascular group (P < 0.0001). In comparing the survival according to PD-ECGF and VEGF gene expression, the median survival time of the patients with positive PD-ECGF expression was significantly shorter than those with negative PD-ECGF expression (P = 0.040). Furthermore, the median survival time of the patients with positive VEGF expression was significantly shorter than those with negative VEGF expression (P = 0.048). However, the Cox multivariate analysis indicated that the IMD and VEGF expression were independent prognostic factors of the various clinicopathologic variables in pancreatic cancer patients (P = 0.0021 and P = 0.0443, respectively).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10188906      PMCID: PMC2362700          DOI: 10.1038/sj.bjc.6690248

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

1.  Angiogenic factor.

Authors:  T Furukawa; A Yoshimura; T Sumizawa; M Haraguchi; S Akiyama; K Fukui; M Ishizawa; Y Yamada
Journal:  Nature       Date:  1992-04-23       Impact factor: 49.962

2.  Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity.

Authors:  K Usuki; J Saras; J Waltenberger; K Miyazono; G Pierce; A Thomason; C H Heldin
Journal:  Biochem Biophys Res Commun       Date:  1992-05-15       Impact factor: 3.575

3.  Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor.

Authors:  F Ishikawa; K Miyazono; U Hellman; H Drexler; C Wernstedt; K Hagiwara; K Usuki; F Takaku; W Risau; C H Heldin
Journal:  Nature       Date:  1989-04-13       Impact factor: 49.962

4.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

5.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

6.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.

Authors:  E Tischer; R Mitchell; T Hartman; M Silva; D Gospodarowicz; J C Fiddes; J A Abraham
Journal:  J Biol Chem       Date:  1991-06-25       Impact factor: 5.157

7.  Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer.

Authors:  C M Barton; P A Hall; C M Hughes; W J Gullick; N R Lemoine
Journal:  J Pathol       Date:  1991-02       Impact factor: 7.996

8.  Cathepsin D and prognosis in breast cancer.

Authors:  A K Tandon; G M Clark; G C Chamness; J M Chirgwin; W L McGuire
Journal:  N Engl J Med       Date:  1990-02-01       Impact factor: 91.245

9.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms.

Authors:  K A Houck; D W Leung; A M Rowland; J Winer; N Ferrara
Journal:  J Biol Chem       Date:  1992-12-25       Impact factor: 5.157

10.  Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression.

Authors:  J Itakura; T Ishiwata; H Friess; H Fujii; Y Matsumoto; M W Büchler; M Korc
Journal:  Clin Cancer Res       Date:  1997-08       Impact factor: 12.531

View more
  98 in total

1.  Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.

Authors:  Birgit Hotz; Marina V Backer; Joseph M Backer; Heinz-J Buhr; Hubert G Hotz
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  Xenon-inhalation computed tomography for noninvasive quantitative measurement of tissue blood flow in pancreatic tumor.

Authors:  Masaru Kubota; Takamichi Murakami; Hiroaki Nagano; Hidetoshi Eguchi; Shigeru Marubashi; Shogo Kobayashi; Hiroshi Wada; Masahiro Tanemura; Keizo Dono; Shoji Nakamori; Masato Sakon; Morito Monden; Masaki Mori; Yuichiro Doki
Journal:  Dig Dis Sci       Date:  2011-09-28       Impact factor: 3.199

3.  Expression and biological function of N-myc down-regulated gene 1 in human cervical cancer.

Authors:  Jing Wang; Jing Cai; Zhimin Li; Sha Hu; Lili Yu; Lan Xiao; Zehua Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

4.  Impact of microvessel density on lymph node metastasis and survival after curative resection of pancreatic cancer.

Authors:  Christoph Benckert; Armin Thelen; Thorsten Cramer; Wilko Weichert; Gereon Gaebelein; Reinhard Gessner; Sven Jonas
Journal:  Surg Today       Date:  2011-11-10       Impact factor: 2.549

5.  Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model.

Authors:  Xuefeng Zhang; Caitlin Connolly; Mark Duquette; Jack Lawler; Sareh Parangi
Journal:  Cancer Lett       Date:  2006-06-06       Impact factor: 8.679

Review 6.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

Review 7.  Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis.

Authors:  Yoko Matsuda; Masahito Hagio; Toshiyuki Ishiwata
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

8.  Correlation of CT enhancement, tumor angiogenesis and pathologic grading of pancreatic carcinoma.

Authors:  Zhong-Qiu Wang; Jie-Shou Li; Guang-Ming Lu; Xin-Hua Zhang; Zi-Qian Chen; Kui Meng
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 9.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

10.  Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.

Authors:  Zhiliang Jia; Yong Gao; Liwei Wang; Qiang Li; Jun Zhang; Xiangdong Le; Daoyan Wei; James C Yao; David Z Chang; Suyun Huang; Keping Xie
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.